Dezocine

CHEMBL1685 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

245.4 g/mol

LogP

3.7

Phase

4

An opioid analgesic used to treat moderate to severe pain by binding to opioid receptors in the central nervous system. It has both agonist and antagonist properties at different opioid receptor types.

الوزن الجزيئي

245,3600 g/mol

LogP

3,70

TPSA

46,30 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Pain Management

آلية العمل

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N

InChI

InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1

Molecular Formula

C16H23NO

HBD / HBA

2 / 2

الروابط القابلة للدوران

0

الذرات الثقيلة

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An opioid analgesic used to treat moderate to severe pain by binding to opioid receptors in the central nervous system. It has both agonist and antagonist properties at different opioid receptor types.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Dezocine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1685. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3033053. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Dezocine على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C16H23NO

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.